Tofacitinib for the Treatment of Alopecia Areata and Its Variants
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02312882|
Recruitment Status : Completed
First Posted : December 9, 2014
Results First Posted : November 6, 2017
Last Update Posted : November 6, 2017
|Condition or disease||Intervention/treatment||Phase|
|Alopecia Areata Alopecia Totalis Alopecia Universalis||Drug: Tofacitinib||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||40 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Tofacitinib for the Treatment of Alopecia Areata and Its Variants|
|Study Start Date :||December 2014|
|Actual Primary Completion Date :||August 2015|
|Actual Study Completion Date :||August 2015|
Participants will receive tofacitinib for 3 months.
Tofacitinib 5 mg tablet taken by mouth twice a day.
- Percent Change in Severity of Alopecia Tool (SALT) Score [ Time Frame: 0 and 3 months ]SALT score range is from 0 (no hair loss) to 100 (100% hair loss). Positive percent change from baseline corresponds to reduction in SALT score.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02312882
|United States, California|
|Stanford, California, United States, 94305|
|Principal Investigator:||Anthony E Oro, M.D., Ph.D.||Stanford University|